Search research articles
Contact Us
Filters
Showing results (471-480 of 583) with videos related to
Page
of 59
Sort By:
Blood
|
November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
Mayo Clinic Proceedings
|
December 17, 2021
Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study
Alan S Go, Kristi Reynolds, Harshith R Avula, et al.
Blood
|
May 4, 2011
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
Robyn Scherber, Amylou C Dueck, Peter Johansson, et al.
The New England Journal of Medicine
|
July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
Claire N Harrison, Peter J Campbell, Georgina Buck, et al.
Blood
|
May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Philip A Beer, Peter J Campbell, Linda M Scott, et al.
The New England Journal of Medicine
|
January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 24, 2021
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study
Teresa N Harrison, Kristi Reynolds, Erin E Hahn, et al.
European Journal of Haematology
|
November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Ruben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
British Journal of Haematology
|
July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N Harrison, Martin Griesshammer, Carole Miller, et al.
Page
of 59
Search research articles
Search
Showing results (471-480 of 583) with videos related to
Sort By:
Page
of 59
Blood
|
November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
Mayo Clinic Proceedings
|
December 17, 2021
Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study
Alan S Go, Kristi Reynolds, Harshith R Avula, et al.
Blood
|
May 4, 2011
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
Robyn Scherber, Amylou C Dueck, Peter Johansson, et al.
The New England Journal of Medicine
|
July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
Claire N Harrison, Peter J Campbell, Georgina Buck, et al.
Blood
|
May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Philip A Beer, Peter J Campbell, Linda M Scott, et al.
The New England Journal of Medicine
|
January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 24, 2021
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study
Teresa N Harrison, Kristi Reynolds, Erin E Hahn, et al.
European Journal of Haematology
|
November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Ruben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
British Journal of Haematology
|
July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N Harrison, Martin Griesshammer, Carole Miller, et al.
Page
of 59